$HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma$

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

Bibliographic Details
Main Authors:	Wendy B.C. Stevens, Katerina Bakunina, Marloes Cuijpers, Martine Chamuleau, Aart Beeker, Rob Fijnheer, Holger Hebart, Hein P.J. Visser, Jeanette K. Doorduijn, Kim Linton, Martin Dreyling, Daphne de Jong, Marie José Kersten
Format:	Article
Language:	English
Published:	Wiley 2020-02-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000325

Internet

http://journals.lww.com/10.1097/HS9.0000000000000325

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

Internet

Similar Items